330 related articles for article (PubMed ID: 27164900)
1. [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis.
Haubner R; Finkenstedt A; Stegmayr A; Rangger C; Decristoforo C; Zoller H; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2005-13. PubMed ID: 27164900
[TBL] [Abstract][Full Text] [Related]
2. PET-Based Human Dosimetry of the Dimeric αvβ3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis.
López-Rodríguez V; Galindo-Sarco C; García-Pérez FO; Ferro-Flores G; Arrieta O; Ávila-Rodríguez MA
J Nucl Med; 2016 Mar; 57(3):404-9. PubMed ID: 26585063
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.
Doss M; Kolb HC; Zhang JJ; Bélanger MJ; Stubbs JB; Stabin MG; Hostetler ED; Alpaugh RK; von Mehren M; Walsh JC; Haka M; Mocharla VP; Yu JQ
J Nucl Med; 2012 May; 53(5):787-95. PubMed ID: 22499613
[TBL] [Abstract][Full Text] [Related]
4. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry.
Buchegger F; Viertl D; Baechler S; Dunet V; Kosinski M; Poitry-Yamate C; Rüegg C; Prior JO
Nuklearmedizin; 2011; 50(6):225-33. PubMed ID: 21989840
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
[TBL] [Abstract][Full Text] [Related]
7. Safety, Dosimetry, and Tumor Detection Ability of
Skovgaard D; Persson M; Brandt-Larsen M; Christensen C; Madsen J; Klausen TL; Holm S; Andersen FL; Loft A; Berthelsen AK; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
[TBL] [Abstract][Full Text] [Related]
8. Primary radiation dosimetry of a novel PET radiopharmaceutical
Cheki M; Gali H
Hell J Nucl Med; 2017; 20(3):241-246. PubMed ID: 29177263
[TBL] [Abstract][Full Text] [Related]
9. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
11. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III.
Hartmann H; Freudenberg R; Oehme L; Zöphel K; Schottelius M; Wester HJ; Wunderlich G; Kotzerke J; Brogsitter C
Nuklearmedizin; 2014; 53(5):211-6. PubMed ID: 25029274
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human Study of [
Clausen MM; Carlsen EA; Christensen C; Madsen J; Brandt-Larsen M; Klausen TL; Holm S; Loft A; Berthelsen AK; Kroman N; Knigge U; Kjaer A
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453899
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process.
Pohle K; Notni J; Bussemer J; Kessler H; Schwaiger M; Beer AJ
Nucl Med Biol; 2012 Aug; 39(6):777-84. PubMed ID: 22444238
[TBL] [Abstract][Full Text] [Related]
15. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.
Mittra ES; Goris ML; Iagaru AH; Kardan A; Burton L; Berganos R; Chang E; Liu S; Shen B; Chin FT; Chen X; Gambhir SS
Radiology; 2011 Jul; 260(1):182-91. PubMed ID: 21502381
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and Radiation Dosimetry of
Garg PK; Lokitz SJ; Nazih R; Garg S
J Nucl Med; 2017 Mar; 58(3):473-478. PubMed ID: 27660145
[TBL] [Abstract][Full Text] [Related]
17. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of
Zhu W; Cheng Y; Jia R; Zhao H; Bai C; Xu J; Yao S; Huo L
J Nucl Med; 2021 Oct; 62(10):1398-1405. PubMed ID: 33579804
[No Abstract] [Full Text] [Related]
18. [⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison.
Knetsch PA; Petrik M; Rangger C; Seidel G; Pietzsch HJ; Virgolini I; Decristoforo C; Haubner R
Nucl Med Biol; 2013 Jan; 40(1):65-72. PubMed ID: 23102540
[TBL] [Abstract][Full Text] [Related]
19. Imaging of α
Grönman M; Tarkia M; Kiviniemi T; Halonen P; Kuivanen A; Savunen T; Tolvanen T; Teuho J; Käkelä M; Metsälä O; Pietilä M; Saukko P; Ylä-Herttuala S; Knuuti J; Roivainen A; Saraste A
J Transl Med; 2017 Jun; 15(1):144. PubMed ID: 28629432
[TBL] [Abstract][Full Text] [Related]
20. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression.
Beer AJ; Haubner R; Wolf I; Goebel M; Luderschmidt S; Niemeyer M; Grosu AL; Martinez MJ; Wester HJ; Weber WA; Schwaiger M
J Nucl Med; 2006 May; 47(5):763-9. PubMed ID: 16644745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
